Investment Rating - The industry investment rating is "Outperform the Market" [3][28] Core Viewpoints - The report emphasizes the potential of AI in healthcare, particularly through the DeepSeek model, which accelerates the implementation of AI in medical settings, enhancing diagnostic efficiency and resource allocation [7][23][27] - The industry is expected to transition from scale expansion to higher-level development, focusing on high-quality growth and long-term investment opportunities [28] Summary by Sections Industry Overview - The medical device sector has shown a monthly increase of 8.67%, outperforming the pharmaceutical sector and the CSI 300 index by 2.26 and 6.04 percentage points respectively [11][15] - The average PE ratio for the medical device sector is 28.93, which is a 9.74% premium over the pharmaceutical sector and a 154.06% premium over the CSI 300 index [15][21] Key Stocks - Major companies highlighted include: - Mindray Medical: EPS of 9.55 in 2023, rated "Buy" [4] - Weili Medical: EPS of 0.66 in 2023, rated "Add" [4] - New Industry: EPS of 2.10 in 2023, rated "Add" [4] - Yuyue Medical: EPS of 2.39 in 2023, rated "Add" [4] - Kefu Medical: EPS of 1.22 in 2023, rated "Add" [4] AI Medical Applications - AI in healthcare is categorized into several applications, including drug development, medical imaging, healthcare robotics, and health management, all aimed at improving service efficiency and quality [25][24] - The report suggests that AI will help address the growing medical demand and resource distribution issues in China, enhancing early disease detection and treatment [24][26] Investment Recommendations - The report recommends focusing on companies with strong innovation capabilities and international expansion potential, such as Mindray Medical, Union Medical, and Weili Medical [28] - It also highlights the importance of AI models like DeepSeek in improving medical efficiency and resource optimization, suggesting attention to companies like BGI and Shengxiang Biological [28]

Investment Ratings - The report provides a "Buy" rating for China Jushi (中国巨石) and United Imaging Healthcare (联影医疗), indicating expected strong performance relative to the market [17][21] - The report maintains a "Buy" rating for Baofeng Energy (宝丰能源) and Kunming Pharmaceutical (昆药集团), suggesting positive growth prospects [33][24] Core Insights - The report highlights the recovery potential of the Hong Kong stock market from the perspective of the AH premium, which has decreased significantly, indicating room for valuation recovery [5][8] - The agricultural sector is experiencing adjustments in global crop production forecasts, with increased corn and wheat production, while rice production is slightly reduced [12][14][15] - China Jushi is positioned to benefit from emerging demand in the fiberglass industry despite traditional demand weaknesses, with expected revenue growth as prices stabilize [17][19] - United Imaging Healthcare is breaking the monopoly in the medical imaging sector, with a strong domestic market share and rapid overseas expansion [21][22] Summary by Sections AH Premium Analysis - The AH premium has gone through three distinct phases since 2010, with significant events influencing its trajectory, such as the launch of the Shanghai-Hong Kong Stock Connect [5][6] - As of March 11, 2025, the AH premium rate is at 132.79, indicating a significant decline from previous highs, suggesting a potential for recovery in Hong Kong valuations [8][9] Agricultural Sector Insights - USDA's March report indicates a global corn production increase of 1.7 million tons to 1.214 billion tons for 2024/2025, driven by favorable conditions in India and other countries [12] - Global wheat production is forecasted to rise by 3.44 million tons to 797 million tons, attributed to improved weather conditions in Australia and other regions [14] - Rice production is slightly adjusted down by 10,000 tons to 533 million tons, with consumption expected to rise [15] China Jushi Overview - China Jushi is the largest fiberglass producer globally, with a comprehensive product range and a recovery in revenue expected as prices stabilize [17][19] - The company is leveraging its cost advantages and global presence to enhance competitiveness in the fiberglass market [19] United Imaging Healthcare Overview - United Imaging Healthcare is rapidly expanding its market share in medical imaging, with a diverse product portfolio and strong growth in both domestic and international markets [21][23] - The company is expected to continue its growth trajectory, driven by increasing demand for imaging services and technological advancements [22][23] Kunming Pharmaceutical Overview - Kunming Pharmaceutical is optimizing its product layout and expanding its market presence, with projected net profits increasing from 6.48 billion yuan in 2024 to 7.45 billion yuan in 2025 [24][25] - The company is focusing on innovation and international expansion to drive future growth [26] Baofeng Energy Overview - Baofeng Energy reported a revenue increase of 13.2% to 32.98 billion yuan in 2024, with net profits rising by 12.2% [33] - The company is expected to benefit from new projects in Inner Mongolia and Xinjiang, enhancing its growth potential [35]

2025 年 3 月 10 日 招银国际环球市场 | 睿智投资 | 行业研究 中国医药 预期药品集采政策优化，期待"创新药目录"落地 MSCI 中国医疗指数 2025 年初至今累计上涨 12.9%，跑输 MSCI 中国指数 7.6%。 受益于国内药品价格政策优化、国内宏观环境改善以及海外降息预期，医药行业有 望在 2025 年继续迎来估值修复。丙类医保目录年内即将落地，创新药将获得更好 的支付环境。医疗设备招标加速复苏，将推动国产医疗设备企业盈利复苏。 估值表 | | | | 市值 | 目标价 | 上行/ | P/E (x) | | P/B (x) | | ROE (%) | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 公司名称 | 股份代码 | 评级 | (百万美元) | | | | (LC) 下行空间 FY25E FY26E FY25E FY26E FY25E FY26E | | | | | | 百济神州 | ONC US | 买入 | 27,422.2 | 359.47 | 40% | 209 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [4]. Core Views - The government has increased support for innovative drugs, which is expected to promote healthy development across various segments of the pharmaceutical industry [6][32]. - The report emphasizes a positive outlook for the pharmaceutical sector, particularly in the context of recent government policies aimed at enhancing healthcare services and drug innovation [27][32]. Summary by Sections Weekly Market Review - The pharmaceutical and biotechnology index rose by 2.02%, outperforming the CSI 300 index by 0.64 percentage points, ranking 18th in industry performance [9]. - Year-to-date, the index has increased by 6.53%, again surpassing the CSI 300 by 6.3 percentage points, ranking 14th [9]. - Sub-sectors such as medical services and medical devices showed significant gains, with medical services up 3.7% and medical devices up 3.29% for the week [13]. Individual Stock Performance - In the A-share market, 321 out of 477 pharmaceutical stocks rose, with notable gainers including Hotgen Biotech (+38.63%) and Berry Genomics (+34.39%) [18]. - In the Hong Kong market, 78 out of 106 pharmaceutical stocks increased, with top performers being HeartFlow Medical-B (+31.87%) and Hengrui Medicine-B (+30.19%) [22]. Industry News and Policies - The government work report highlighted the need for a collaborative approach to healthcare, emphasizing the integration of medical services, insurance, and pharmaceuticals [27]. - Key policies include optimizing drug procurement, enhancing quality assessments, and increasing financial support for basic medical insurance [33]. Weekly Insights - The report reiterates a bullish stance on the pharmaceutical sector, particularly in light of government initiatives to support innovative drug development and improve healthcare financing [32][34]. - Specific recommendations include focusing on companies in various segments such as raw materials, chemical preparations, and medical services, with suggested stocks like Hengrui Medicine and WuXi AppTec [34].

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 暂定议程 报名：首届全球心血管大会 | 奖项报名倒计时 报名：首届全球骨科大会 | 奖项报名倒计时 年初以来，在DeepSeek的推动下，各行各行纷纷加入AI浪潮。 近日， 华为 宣布正式成立"医疗卫生军团" ，用AI大模型为中国医院装上"智能心 脏"，提升医疗效率和质量 。该军团旨在整合华为在5G、云计算、AI大模型等领域的技术积累，重点构建AI辅助诊断解决方案体系，推动医疗大模型 在临床场景的应用。 据世界卫生组织预测，到 2030 年全球医疗数据量将增长至 2.3 万亿 GB ，但传统医疗系统对数据的处理能力严重滞后。 华为的医疗军团模式，正是 以技术融合填补这一鸿沟，通过"端到端"的垂直整合 ，实现从实验室到临床的快速落地。 # 三 大核 心 技术底 牌 虽然华为本身并未发布任何医疗大模型，只是为行业训练大模型提供解决方案。但面对这块万亿蛋糕，华为的野心远不止于技术供应商，它要成为医 疗智能化的"操作系统"。 一旦华为在技术、生态、政策三端协同突破，或将推动中国医疗从"跟跑"转向"领跑 "。 华为的"军团制度"自2021年实施以来， ...

Investment Rating - The report suggests a positive outlook for the pharmaceutical sector, indicating a focus on investment opportunities within the industry [4][6]. Core Insights - The pharmaceutical and biotechnology sector has shown initial signs of a fundamental reversal, with the index experiencing a cumulative increase of +3.0% year-to-date as of March 10, 2025, underperforming the broader market by 3.0 percentage points [4][11]. - The report highlights the transformative impact of AI technologies in the healthcare and pharmaceutical sectors, emphasizing their role in enhancing diagnostic precision, research efficiency, and service accessibility [4][49]. - The report recommends focusing on specific segments within the pharmaceutical industry, including CXO and upstream companies, medical devices, innovative drugs, medical services, and AI-driven companies [4][81]. Summary by Sections 1. Industry Data and Trends - The report notes that the basic medical insurance fund achieved a balance in revenue and expenditure in 2024, with total revenue reaching CNY 3.48 trillion (up 4.4% year-on-year) and total expenditure at CNY 2.97 trillion (up 5.5% year-on-year) [19]. - The number of hospital visits and discharges in 2024 has returned to pre-pandemic levels, with cumulative hospital visits reaching 3 billion (up 9.1% year-on-year) [24]. - The medical device market has shown signs of recovery, with a significant increase in procurement bids starting in December 2024 [28]. 2. AI Integration in Healthcare - AI technologies are reshaping the pharmaceutical landscape, with companies like RunDa Medical and United Imaging leveraging AI for enhanced medical imaging and patient management [4][51][59]. - The report discusses various applications of AI in drug development, diagnostics, and healthcare services, highlighting the potential for improved efficiency and patient outcomes [4][49]. 3. Valuation and Investment Recommendations - The pharmaceutical sector's current price-to-earnings (P/E) ratio stands at 31.4x, indicating a relatively low valuation compared to historical levels [14]. - Specific companies are highlighted for investment consideration, including WuXi AppTec, Mindray Medical, and Innovent Biologics, across various sub-sectors [4][81].

Investment Rating - The report does not explicitly state an investment rating for the specialized equipment industry or the specific company being analyzed [1]. Core Insights - The company operates two major manufacturing bases in Shenzhen and Changzhou, currently running at full capacity, with plans for an additional intelligent manufacturing base in Changzhou to produce 1.81 million industrial control products [19]. - The company is actively expanding its international market presence, focusing on regions such as the Middle East, Europe, Southeast Asia, and the Americas, with established local marketing teams in India and Indonesia [19]. - The company is positioned to meet the increasing demand for domestic products in the high-end manufacturing sector, with its human-machine interface (HMI) products capable of competing with international brands [20]. - The medical imaging equipment sector is identified as a stable strategic industry for the company, with ongoing collaborations with major clients like Siemens and United Imaging, and plans to expand into new client relationships as domestic healthcare develops [20]. Summary by Sections 1. Basic Research Information - The research was conducted on the company Buke Co., Ltd., which belongs to the specialized equipment industry, on March 4, 2025 [13]. 2. Detailed Research Institutions - Various institutions participated in the research, including Zhejiang Securities, Huaxi Securities, and several fund management companies [14][15]. 3. Research Institution Proportions - The report does not provide specific data on the proportions of research institutions involved [17]. 4. Main Content Information - The company is focused on expanding its production capacity and enhancing its international market strategy, with a strong emphasis on high-end manufacturing and medical imaging sectors [19][20].

丨 来源：新华社客户端 2025-03-07 一对一协助排忧解难 深交所持续走访上市公司 上交所启动百家民营企业大调研 深入一线问计问需 切实推动解决实际问题 增强民企发展信心 近期，深交所持续走访调研上市公司，深入了解上市公司当前遇到的实际困难、问题和诉 求建议，针对性提供一对一"答疑解惑"，着力协助上市公司排忧解难，进一步支持上市公司更 好发展。 记者获悉，自2024年11月以来至目前，深交所已走访调研北京、上海、广东、浙江、江 苏、山东等地逾90家上市公司。汇川技术、德赛西威、三花智控等相关上市公司在与深交所交 流时表示，将好好把握来之不易的优势，保持战略定力，以实现更长远的发展目标，为投资者 创造更多价值。 走访调研中，深市上市公司介绍了近年来聚焦主业、深耕产业实现高质量发展的实践经 验，提出了在关键核心技术攻关、开辟发展新领域新赛道、塑造发展新动能新优势等方面存在 的问题和困难，还对如何利用资本市场推动自主创新、塑造发展新动能新优势提出意见建议。 不久前，德赛西威43.99亿元定增获证监会批文，是资本市场支持下加速产品智能化升级 的案例之一。"本次向特定对象发行股票有利于德赛西威通过有序的产能扩张提 ...

摘要 Q&A 联谊医疗的发展历程及其在高端医学影像设备领域的成就是什么？ 联谊医疗成立于 2011 年，经过多年的高强度研发投入，已经形成了围绕高端医 学影像设备的丰富产品线，包括 MR、CT、XR、PET MR 等诊断产品。公司在 2019 至 2023 年间实现了迅猛增长，复合收入增速接近 40%。2020 年公司扭亏 • 联影医疗 2019-2023 年收入复合增速近 40%，归母净利润复合增速近 30%， 但 2024 年国内收入受医疗规划影响承压。设备毛利率从 2019 年的 13.2% 提升至 2023 年的 47.8%，维修业务收入占比从 6%增至 12%，毛利率升至 61.7%。 • 公司股权结构相对集中，实控人薛敏间接控股 27.63%，上海国资委持股 16.38%。管理层多具专业背景及国际影像巨头工作经验。2024 年推出限制 性股票激励计划，覆盖 11.2%员工，业绩考核目标为 24-26 年营收较 23 年 分别增长不低于 20%、44%及 72.8%。 • 2019-2023 年，CT、MR、MI、XR、RT 收入复合增速分别为 41%、38%、50%、 20%、134%。截至 24 ...

Investment Rating - The report assigns an investment rating of "Recommended" for the pharmaceutical and biotechnology industry [3][33]. Core Insights - The "AI + Healthcare/Pharmaceutical" theme continues to gain traction, with short-term momentum expected to persist. The report highlights significant stock performance in the sector, with the pharmaceutical and biotechnology sector (SW) rising by 2.71%, outperforming the CSI 300 index, and all sub-sectors showing positive growth, particularly in medical services [3][4]. - In the U.S., Tempus AI, a representative company in medical AI, saw a weekly increase of approximately 30% and over 160% year-to-date, driving the momentum of the medical AI concept. In China, companies like KingMed Diagnostics and Dian Diagnostics announced collaborations with DeepSeek, indicating a shift towards the commercialization of AI applications in healthcare [4][3]. - The report emphasizes investment opportunities in sub-sectors such as "AI + Medical Imaging," "AI + Diagnostic Services," and "AI + Drug Development," recommending key companies including United Imaging, Mindray, BGI Genomics, and WuXi AppTec [3][4]. Industry Performance Tracking - The pharmaceutical and biotechnology sector (SW) rose by 2.71% in the week of February 10-14, ranking 5th among 31 Shenwan primary industries. The CSI 300 index increased by 1.19% during the same period [5][6]. - All sub-sectors experienced growth, with medical services leading at +6.51%, followed by medical devices at +4.81%, and pharmaceutical commerce at +4.18% [5][6]. - Notable individual stock performances included Dian Diagnostics (+46.29%), Mian Health (+31.58%), and United Imaging (+27.33%) [6]. Industry Dynamics and Key Company Tracking - The National Healthcare Security Administration released a list of key tasks for 2025, focusing on efficient medical insurance processes and direct settlements for collected drugs and consumables [7]. - The retail terminal drug sales scale in China is projected to reach 574 billion yuan in 2024, with a growth rate of 3.7%, indicating a slowdown in growth due to demographic and economic factors [8]. - The report also notes significant collaborations, such as Baiyang Pharmaceutical's agreement with Roche for the exclusive marketing rights of a targeted cancer drug in mainland China [9][11]. Industry Data Tracking - The report tracks various industry metrics, including the basic medical insurance fund income, which reached 28,507.29 billion yuan in 2024, showing a year-on-year growth of 5% [15][16]. - The domestic pharmaceutical manufacturing industry achieved a total revenue of 25,298.50 billion yuan in 2024, with profit totals declining by 1.1% year-on-year [17].